Zai Lab to seek China approval for cervical cancer therapy after positive trial data

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab vedotin) in China after patients who took part in the Chinese segment of its global Phase 3 innovaTV 301 study showed encouraging results.